Japan health panel recommends approval of Pfizer coronavirus vaccine

Health Minister Norihisa Tamura says a formal approval is expected Sunday

Pfizer
Pfizer plans to ask the Food and Drug Administration for emergency authorization of the two-dose vaccine later this month
AP Tokyo
1 min read Last Updated : Feb 12 2021 | 10:08 PM IST

Japan's health minister says the efficacy of Pfizer vaccine was endorsed by a ministry panel, paving the way for a final approval within days.

Health Minister Norihisa Tamura says a formal approval is expected Sunday. The vaccine is already administered in the U.S. and many other countries since December.

Vaccines are considered key to holding the delayed Olympics this summer. Japan is expected to receive 144 million doses from Pfizer, 120 million from AstraZeneca and about 50 million from Moderna before the end of this year, enough to cover its population.

Japan must rely on imports, many subject to the EU's export control, and a cause for concern about supplies. Vaccines developed by Japan are still in the early stages.

About 20,000 front-line medical workers at hospitals in Japan will get their first shots beginning the middle of next week.

About 3 million other medical workers will be next, followed by elderly people getting their shots in April. By June, it's expected all others will be eligible.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :JapanPfizerCoronavirus Vaccine

First Published: Feb 12 2021 | 10:00 PM IST

Next Story